Frazier Life Sciences Management, L.P. Gritstone Bio, Inc. Transaction History

Frazier Life Sciences Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.28 - $2.85 $512,000 - $1.14 Million	-400,000 Reduced 27.95%	1,030,878 $2.1 Million
Q3 2023 Nov 14, 2023	SELL	$1.19 - $2.26 $1.16 Million - $2.19 Million	-970,836 Reduced 40.42%	1,430,878 $2.46 Million
Q2 2023 Aug 14, 2023	SELL	$1.66 - $3.03 $4.58 Million - $8.36 Million	-2,760,634 Reduced 53.48%	2,401,714 $4.68 Million
Q4 2022 Feb 03, 2023	SELL	$2.17 - $3.92 $162,750 - $294,000	-75,000 Reduced 1.43%	5,162,348 $17.8 Million
Q1 2022 May 16, 2022	BUY	$4.03 - $12.19 $21.1 Million - $63.8 Million	5,237,348 New	5,237,348 $21.6 Million

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.